To evaluate the efficacy and safety of CofNovex plus [EMA] syrup

The cough and cold are very widespread conditions and a common purpose for advice in general practice. Utmost often the sign and symptoms of cough are produced by acute viral airway infection and the course is frequently benign. But it can be converted into bacterial super-infection and can cause acute bronchitis. Herbal medicines are used to treat symptoms of the cough and cold, and among these medicines Ivy leaf is used to treat mucous discharge and irritation in throat due to the cough and cold. In addition to synthetic substances such as acetylcysteine, carbocisteins, ambroxol and bromhexine, herbal medicines contain saponins, which are used in these indications. Not just Ivy, but also the marshmallow and mustard seeds used for these indications. This clinical trial was conducted in 220 patients, in which 110 receive the CofNovex plus European Medicines Agency [EMA] syrup and 110 receive the placebo. The age range of patients was 3 years to above 15 years. The sample paired t-test was applied to evaluate the significant level. CofNovex plus [EMA] syrup was very effective in treating cough and cold symptoms. The new treatment CofNovex plus [EMA] syrup was safe and well tolerated in patient at given specific age group

Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients

Type 2 diabetes mellitus [T2D] is a chronic metabolic disease regarded as insulin resistance and progressive failure of ? cells. Beta cells secretagogues are useful to reach satisfactory glycemic control. Glimepiride is a secondgeneration sulfonylurea excites pancreatic beta cells to discharge insulin. Glimepiride may be safer to use in patients with cardiovascular disease due to lack of destructive effects on ischemic preconditioning. It is effective in dropping fasting plasma glucose [FPG], postprandial glucose and glycated hemoglobin levels and is a useful and cost-effective option treatment for the management of T2D. Total 40 patients were selected from OPD setting at RSNPMTS Endocrinology center Ministry of Health Republic of Uzbekistan, and corresponding to criteria for inclusion / exclusion. 10 patients with T2D switched from receiving other forms of Glimepiride [Amaryl] on an identical dose of GlucoNovax in combination with biguanides [Metformin] denoted as group 1. At the same time the dose of biguanides [Metformin] was not altered for the period of the study. 10 patients with T2D switched from receiving other forms of Glimepiride [Amaryl] on an identical dose of GlucoNovax denoted as group 2.10 patients with T2D switched to the drug GlucoNovax from the drug Glibenclamide denoted as group 3. The control group received monotherapy with Amaryl it consist of 10 patients with T2D denoted as group 4. The severity of diabetic complaints in patients receiving the combination drug GlucoNovax with metformin significantly decreased by the end of the observation period and had an inclination to reduction in the 2nd and 3[rd] groups, along with the control group. 30 patients, receiving the drug Gluco Novax, 7 achieved blood glucose level parameters that corresponding to the high effectiveness of the drug [4 of them from 1[st] group [GlucoNovax+ Metformin], 1 in the 2[nd] group, 2 in the 3[rd] group]. 6 patients achieved blood glucose levels parameters, meeting the criteria of moderate effectiveness of the drug [4 of them from 1[st] group, 1 patient in the 2[nd] and 1 patient in the 3[rd] groups]. The given result may be, associated with initially high levels of compensation of carbohydrate metabolism, as well as a more effective influence on combination treatment with Metformin. The drug GlucoNovax appears to be an effective hypoglycemic agent in the treatment of T2D with good tolerability

Study on camphor-free natural topical medicine for upper respiratory tract infections in children

Upper respiratory tract infections [URTI] are the most common acute illnesses that are often of viral origin. Cough and chest congestion are the common symptoms of this disease. Children are prescribed with drugs that are considered to relive the symptoms of this disease. The topical medications contain vegetable camphor for more than a century that relieve chest congestion and cough caused by URTI. The use of camphor in such products remains questionable especially in children who are more sensitive to its side effects. Herbion "Chest Rub" for children is a camphor-free formulation that contains eucalyptus oil mixture, menthol, turpentine and clove oils and is used to relieve symptoms of URTI. The objective of the present investigation was to determine the effectiveness of the chest rub in children suffering with congestion and cough caused by URTI. The study compared the results of the chest rub applied to a group of infected children with a placebo group. Patients were selected randomly on the basis of the criteria set for the study. The results indicated that the chest rub was quite effective in majority of the cases in relieving the symptoms of URTI as compared to the placebo group